TG-01 is under clinical development by Circio Holding and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TG-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TG-01 is under development for the treatment of multiple myeloma, pancreatic cancer and unspecified indication. It is administered as an intradermal and subcutaneous injection. It consists of seven RAS-mutated peptides and the immune-stimulator molgramostim targeting RAS mutations. The neoantigen vaccine is based on oncogenic amino acid substitutions at position 12 or 13 in p21 RAS. It was also under development for treatment of resected adenocarcinoma of the pancreas as adjuvant therapy and cancer in combination with TG-02, CPI synergy and PD-1.
Circio Holding overview
Circio Holding, formely Targovax, is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG01, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline product for solid tumor indications. It also provides TG02 and ONCOS-200 for other cancer indications. Targovax develops immunotherapies based on treatment approaches harnessing the patient’s immune system to target cancer cells, which include a virus-based immunotherapy platform based on engineered oncolytic viruses for solid tumors; and a peptide-based immunotherapy platform for RAS-mutated cancers. The company has operations in Norway and Finland. Circio is headquartered in Oslo City, Oslo, Norway.
For a complete picture of TG-01’s drug-specific PTSR and LoA scores, buy the report here.